GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exelixis Inc (LTS:0IJO) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Exelixis (LTS:0IJO) Future 3-5Y EPS without NRI Growth Rate : 17.87 (As of May. 18, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Exelixis Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Exelixis's Future 3-5Y EPS without NRI Growth Rate is 17.87.

Competitive Comparison of Exelixis's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, Exelixis's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Exelixis's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exelixis's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Exelixis's Future 3-5Y EPS without NRI Growth Rate falls into.


;
;

Exelixis  (LTS:0IJO) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Exelixis Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Exelixis's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Exelixis Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exelixis Inc (LTS:0IJO) » Definitions » Future 3-5Y EPS without NRI Growth Rate
Comparable Companies
MRNA ASND INCY BMRN INSM TECH ROIV CORT HALO MDGL VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
EXEL:USA EX9:Germany EX9:Germany
Address
1851 Harbor Bay Parkway, Alameda, CA, USA, 94502
Website
https://www.exelixis.com
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Exelixis Headlines

No Headlines